Latest Breaking News On - Yung shin pharmaceutical industrial co - Page 1 : comparemela.com

Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention

Ticagrelor alone outperforms 12-month DAPT for reducing bleeding with no increased risk

United statesNew yorkMedtronic corpIcahn school of medicine at mount sinaiYung shin pharmaceutical industrial coChinese society of cardiologyShenzhen salubris pharmaceuticals co ltdNational natural scientific foundation of chinaAmerican college of cardiology annual scientific sessionAmerican collegeAnnual scientificGregg stoneIcahn schoolMount sinaiChinese societyNational natural scientific foundation

Study shows reduced bleeding risk with ticagrelor monotherapy after percutaneous coronary intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology's Annual Scientific Session.

United statesNew yorkChinese society of cardiologyIcahn school of medicine at mount sinaiYung shin pharmaceutical industrial coShenzhen salubris pharmaceuticals co ltdMedtronic corpAmerican college of cardiologyAmerican college of cardiology annual scientific sessionNational natural scientific foundation of chinaAmerican collegeAnnual scientificIcahn schoolMount sinaiChinese societyNational natural scientific foundation

Study Suggests Most Patients with Acute Coronary Syndromes Can Safely Stop Aspirin One Month After Percutaneous Coronary Intervention

People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one m..

United statesNew yorkAmerican college of cardiologyChinese society of cardiologyShenzhen salubris pharmaceuticals co ltdAccreditation servicesNational natural scientific foundation of chinaIcahn school of medicine at mount sinaiYung shin pharmaceutical industrial coMedtronic corpAmerican college of cardiology annual scientific sessionSuggests most patientsAlphagalileo readerStandard levelPremium levelAmerican college

TLC and Strides partner to launch Liposomal Amphotericin B in India

TLC and Strides partner to launch Liposomal Amphotericin B in India
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

Keelung hongBarbara liGeorge yehYung shin pharmaceutical industrial coStelis biopharma private limitedStrides pharma science ltdStrides pharma science limitedCentral drugs standard control organizationTime zoneDrug applicationAmphotericinb liposomeManaging directorGeneral managerபார்பரா லிஜார்ஜ் ஆமாம்யுங் தாடை மருந்து தொழில்துறை இணை

Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India

Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India
equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.

George yehSharvil patelYung shin pharmaceutical industrial coCadila healthcare ltdCentral drugs standard control organizationBlack fungusTime zoneAmphotericinb liposomeNew drug applicationYung shin pharmaceutical industrialManaging directorஜார்ஜ் ஆமாம்ஷார்வில் படேல்யுங் தாடை மருந்து தொழில்துறை இணைகாடிலா சுகாதாரம் லிமிடெட்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்